Literature DB >> 26321091

Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers.

Abhishek C Sawant1, Anneline S J M Te Riele1, Crystal Tichnell1, Brittney Murray1, Aditya Bhonsale1, Harikrishna Tandri1, Daniel P Judge1, Hugh Calkins1, Cynthia A James2.   

Abstract

BACKGROUND: Endurance exercise is associated with adverse outcomes in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Exercise recommendations for family members remain undetermined.
OBJECTIVE: The purposes of this study were to determine if (1) endurance exercise (Bethesda class C) and exercise intensity (metabolic equivalent hours per year [MET-Hr/year]) increase the likelihood of fulfilling 2010 Task Force Criteria and ventricular arrhythmias/implantable cardioverter-defibrillator shock (ventricular tachycardia/ventricular fibrillation [VT/VF]), and (2) exercise restriction to the American Heart Association (AHA)-recommended minimum for healthy adults is associated with favorable outcomes of at-risk family members.
METHODS: Twenty-eight family members of 10 probands inheriting a PKP2 mutation were interviewed about exercise from age 10. Exercise threshold to maintain overall health was based on the 2007 AHA guidelines of a minimum 390 to 650 MET-Hr/year.
RESULTS: After adjustment for age, sex, and family membership, both participation in endurance athletics (odds ratio [OR] 7.4, P = .03) and higher-intensity exercise (OR = 4.2, P = .004) were associated with diagnosis (n = 13). Endurance athletes were also significantly more likely to develop VT/VF (n = 6, P = .02). Family members who restricted exercise at or below the upper bound of the AHA goal (≤650 MET-Hr/year) were significantly less likely to be diagnosed (OR = 0.07, P = .002) and had no VT/VF. At diagnosis and first VT/VF, family members had accumulated 2.8-fold (P = .002) and 3.5-fold (P = .03), respectively, greater MET-Hr exercise than the AHA-recommended minimum. Those who developed VT/VF had performed particularly high-intensity exercise in adolescence compared to unaffected family members (age 10-14: P = .04; age 14-19: P = .02).
CONCLUSION: The results of this study suggest restricting unaffected desmosomal mutation carriers from endurance and high-intensity athletics but potentially not from AHA-recommended minimum levels of exercise for healthy adults.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmia; Arrhythmogenic right ventricular cardiomyopathy; Arrhythmogenic right ventricular dysplasia; Desmosome; Exercise; Plakophilin-2

Mesh:

Substances:

Year:  2015        PMID: 26321091     DOI: 10.1016/j.hrthm.2015.08.035

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  17 in total

Review 1.  Advances in the Diagnosis and Management of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy.

Authors:  Gabriela M Orgeron; Hugh Calkins
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

2.  Exercise Dose Associated With Military Service: Implications for the Clinical Management of Inherited Risk for Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Elena M Segre; Lydia D Hellwig; Clesson Turner; Craig P Dobson; Mark C Haigney
Journal:  Mil Med       Date:  2020-09-18       Impact factor: 1.437

Review 3.  Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report.

Authors:  Perry M Elliott; Aris Anastasakis; Angeliki Asimaki; Cristina Basso; Barbara Bauce; Matthew A Brooke; Hugh Calkins; Domenico Corrado; Firat Duru; Kathleen J Green; Daniel P Judge; David Kelsell; Pier D Lambiase; William J McKenna; Kalliopi Pilichou; Alexandros Protonotarios; Jeffrey E Saffitz; Petros Syrris; Hari Tandri; Anneline Te Riele; Gaetano Thiene; Adalena Tsatsopoulou; J Peter van Tintelen
Journal:  Eur J Heart Fail       Date:  2019-06-18       Impact factor: 15.534

4.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Back Sternick Eduardo; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong-Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti Mac Intyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Pablo Ochoa Juan; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  J Arrhythm       Date:  2022-05-31

5.  Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.

Authors:  Lauren Eberly; Lohit Garg; Mahesh Vidula; Nosheen Reza; Sheela Krishnan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2021-09-18

6.  Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

Authors:  Deniz Akdis; Corinna Brunckhorst; Firat Duru; Ardan M Saguner
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

Review 7.  Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy.

Authors:  Hugh Calkins; Domenico Corrado; Frank Marcus
Journal:  Circulation       Date:  2017-11-21       Impact factor: 29.690

8.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

9.  Nature and Nurture in Arrhythmogenic Right Ventricular Cardiomyopathy - A Clinical Perspective.

Authors:  Cynthia A James
Journal:  Arrhythm Electrophysiol Rev       Date:  2015-12-01

Review 10.  [Prevention of sudden cardiac death].

Authors:  Alireza Sepehri Shamloo; Patrick Dilk; Nikolaos Dagres
Journal:  Herz       Date:  2022-03-11       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.